NTI-1309

N/A

Report date: 2025/09/12 11:25:08

Base Information

Drug NameNTI-1309
Drug Alias Name64Cu-LNTH-1363SNTI-1309LNTH-1363S
ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Copper > 64Cu +[4] 
Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNoria Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLantheus Medical Imaging Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A